Exam 1 Flashcards
Ch.1
How to bring a prescription drug to market?
1-2 years to patent, send IND (investigative new drug) to FDA, Phase 1-3; if pass all 3 phases, NDA (new drug application) - takes 1 year to get [where Thalidomide got caught up]; marketing and sent to public; TOTAL = around 9 years
Ch.1
Monoclonal Antibodies uses in pathologic conditions?
cancer, autoimmune diseases
Part of cell that engulfs the receptor and drug together?
Clatherin encoated pit
4 Main Causes of Drug Variation?
Alteration (ADME, age, disease, sex, weight), Varied Concentration of Endogenous Ligand, Alteration in number or function of receptors, and Changes in Downstream Receptor (LARGEST AND MOST IMPORTANT)
Ch.1
Role of Drug Carriers?
Carry a drug across the membrane if needed (non-lipid soluble)
Drug Examples of Zero Elimination
Ethanol, phenytoin, salicylates
What is constant in zero order elimination?
ROE is constant
GCPRs Cascade
Know how to draw; G-PROTEIN activates cascade via ALPHA SUBUNIT
Ch.3
Volume of Distribution (Vd)
The space available in body to contain the drug; how much stayed in the blood vs how much went elsewhere? Shows preference to where drug will best absorb
Zero Order Elimination
ROE is constant; so much drug in body, receptors are completely saturated and you cannot get rid of the drug fast enough; Ex. Every hour, body gets rid of 150 mg of drug (ROE)
Ch.3
Bioavailability (F)
Ch.1
Pharmacodynamics
What the drug does to the body?
-Dose response
2 Outcomes of Desensitization within the Cell?
Can be recycled or a Lysosome will degrade the receptor
Ch.1
Toxins vs Poisons
Toxins - biological; puffer fish, bee, mushrooms
Poisons - non-biological; arsenic/lead
Ch.1
Paracelsus Quote
“The dose makes the poison”
Ch.1
Exogenous vs Endogenous
Ex - Outside body (norepi, epi, propanolol)
End - Inside body (norepi, epi)
Ch.3
Rate of Elimination (ROE)
The speed at which the drug is eliminated from the body
Ch.2
Ligand Gated Ion Channel
Ligand Gated - Contains ionotropic or metabotropic; ligand opens the channel, and when it leaves, the channel is shut
What are the 4 ways drugs get across barriers?
Aqueous diffusion, Lipid diffusion, Special Carriers, Exocytosis (Clatherin coated pit), Endocytosis (merge of vesicle with membrane)
Ch.1
Competitive Inhibitor
an inhibitor that competes to bind at the active site with an agonist
Voltage Gated Ion Channel
Found in excitable cells (neurons, muscle, endocrine); closed @ RMP; based on ion selectivity; 2 gates, upper and lower; When Na+ gets close to the channel, the charge opens it up to allow Na+ in. The bottom gates shuts first after, then both gates completely shut and the whole process starts over again
Ch.2
Desensitization Definition
Drug bound to receptor, but cell shuts down signaling process. Decrease effectiveness of drug; protective mechanism; if constantly being signaled, has process where cell can shut down the signals
Ch.1
Pharmacokinetics - ADME
Absoprtion
Distribution
Metabolism
Excretion
Ch.1
Father of Western Medicine
Hippocrates
Ch.1
Inverse Agonist
STRONG! Binds to same receptor as agonist, but produces opposite response: binds to inactive form of the receptor. Completely shuts down the receptor
Ch.1
Covalent Bond
Strongest; share same chemicals or ions; irreversible; Less specificity
Ch.1
Racemic Mixture
Mixture between different mirror Isomers of a drug. Ex: R-Ketamine (more toxic) and S-Ketamine (4x more potent). Done by rotating the molecules
How to Calculate Therapeutic Index of a Drug?
Td50/Ed50: Wider = safer; narrow = more toxic
Competitive Inhibitor vs Allosteric (non-competitive) Inhibitor
Competitive - Blocks @ the active site [A+B]; surmountable; Countered by increasing agonist
Allosteric - Blocks @ site other than active site [A+D]; insurmountable; irreversible
Ch.3
Concentration (C)
Sub-defined to: C in blood, C in plasma, C in H2O (unbound)
Ch. 1
Electrostatic Bond
Most common; bond based on ionic charges, hydrogen, Van der Waals
Ch.1
Regulation of Prescription Drugs
Have to have licensed provider; viewed by public as “more effective”; increased risk for toxicity
What is constant in 1st order elimination?
CL is constant
Ch.1
Regulation of OTC Drugs
Able to get freely; less risk for toxicity due to usually wider TI
Allosteric
Bind not @ active site of the receptor. Non-competitive; Insurmountable; Irreversible
Ch.2
Inotropic Ion Channel
More common; ligand binding and channel on same protein; nAch receptor in skeletal muscle; Sux binds to this receptor
Ch.3
4 different ways a drug gets across barriers
Aqueous Diffusion, Lipid Diffusion, Special Carriers, Endocytosis (Clatherin Coated Pit) and Exocytosis (merge vesicle with membrane)
Ch.1
Allosteric Inhibitor
Binds outside of Active Site on Receptor Protein
1st Order Elimination
Drug slowly leaves body; CL remains constant (Ex. Every hour, 12% leaves the body)
Agonist
Activator; bind to similar ligand endogenous in the body
Ch.1
Partial Agonist
Weaker than a full agonist; Antagonist in presence of full agonist. Lower intrinsic activity than full agonist
Ex: Epi with Partial Agonist = Decreased effect of Epi
Ch.2
Metabotropic Ion Channel
Ligand activates GCPR –> 2nd messenger opens channel (cAMP binds to channel and opens)
Receptor
Component that interacts with drug and initiates a chain of events that lead to drug observed effect
Ch.3
Target Concentration (TC)
Ch.3
Half-Life (T1/2)
The time it takes for 50% of the drug to be eliminated from the body
Ch.1
How can a partial agonist also be an antagonist?
Partial agonist, when in presence of agonist, turns into an antagonist. This is because the 2 compete, thus decreasing the desired effect of the med. The partial agonist prevents the agonist from accessing the receptor
Ch.1
Pharmacogenomics
Study of genetic profile to see how body will respond to certain drug given
Ch.2
The Molecular Components of Desensitization in the
GPCR
Betaerestin
Clatherin Coated Pit
Ch.2
Types of Ligands that Bind to Receptors Inside the Cell
Gas (NO activated within cell to dilate smooth muscle and decreased BP) and Lipid Soluble Agents (Steroids)
Ch.1
Role of the FDA
To regulate drugs and make sure they are safe and effective; reviews claims and makes recommendations
Ch.1
Most common drug carriers in the blood
Albumin - acid drug binding
A1-Acid Glycoprotein - basic drug binding
Lipoproteins - neutral drug binding
Elimination of the drug is based off of what?
Clearance of the drug
Metabotropic Ion Channel
Ligand activates GCPR; 2nd messenger opens up ion channel’ Ex. cAMP binds to ion channel to open up